Simone Belmonti

Simone Belmonti

Auto-generated profile, based on publicly available information

Simone Belmonti

Istituto Clinica Malattie Infettive Università Cattolica del Sacro Cuore Roma Italia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
ABAlberto Borghetti
Alberto Borghetti
Andrea CalcagnoAndrea Calcagno
Andrea Calcagno
FLFrancesca Lombardi
Francesca Lombardi
Jessica CusatoJessica Cusato
Jessica Cusato
SBS Belmonti
S Belmonti
SGS Di Giambenedetto
S Di Giambenedetto
Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs. A cross-sectional cohort of HIV-positive patients treated with a dolutegravir-containing regimen underwent determination of allelic discrimination for SLC22A2 808 C → A polymorphism and dolutegravir Ctrough. The Symptom Checklist-90-R [investigating 10 psychiatric dimensions and reporting a general severity index (GSI)], a self-reported questionnaire and the Mini-International Neuropsychiatric Interview were offered to investigate current NPs. The effects of dolutegravir Ctrough and the SLC22A2 gene variant on NPs were explored by multivariable logistic regression. A cohort of 203 patients was analysed: 71.4% were male, with median age 51 years and 11 years of ART exposure. Median time on dolutegravir was 18 months. Dolutegravir was associated with different antiretroviral combinations (mainly lamivudine, 38.9%, and abacavir/lamivudine, 35.5%). SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008). Other NPs were not associated with SLC22A2 polymorphism or dolutegravir Ctrough. A variant of the OCT2-encoding gene, in addition to or in synergy with higher dolutegravir Ctrough, is associated with a set of NPs observed during dolutegravir therapy.

22 February 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
SBStefania Bellino
Stefania Bellino
ABAlberto Borghetti
Alberto Borghetti
FLFrancesca Lombardi
Francesca Lombardi
LCLaura Camoni
Laura Camoni
ACArturo Ciccullo
Arturo Ciccullo
SGS. Di Giambenedetto
S. Di Giambenedetto
Here we evaluated hospitalisation rates and associated risk factors of human immunodeficiency virus (HIV)-infected individuals who were followed up in an Italian reference hospital from 1998 to 2016. Incidence rates (IR) of hospitalisations were calculated for five study periods from 1998 to 2016. The random-effects Poisson regression model was used to assess risk factors for hospitalisation including demographic and clinical characteristics. To consider that more events may occur for the same subject, multiple failure-time data analysis was also performed for selected causes using the Cox proportional hazards model. We evaluated 2031 patients. During 13 173 person-years (py) of follow-up, 3356 hospital admissions were carried out for 756 patients (IR: 255 per 1000 py). IR decreased significantly over the study period, from 634 in 1998–2000 to 126 per 1000 py in 2013–2016. Major declines were detected for AIDS-defining events, non-HIV/AIDS-related infections and neurological diseases. Older age, female sex, longer HIV duration and HCV coinfection were associated with a higher hospitalisation risk, whereas higher CD4 nadir and antiretroviral therapy were associated with a reduced risk. Influence of advanced HIV disease markers declined over time. Hospitalisation rates decreased during the study period in most causes. The relative weight of hospitalisations for non-AIDS-related tumours, cardiovascular, respiratory and kidney diseases increased during the study period, whereas those for AIDS-defining events declined.

4 May 2019 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
FLFrancesca Lombardi
Francesca Lombardi
SBSimone Belmonti
Simone Belmonti
ABAlberto Borghetti
Alberto Borghetti
ACArturo Ciccullo
Arturo Ciccullo
GBGianmaria Baldin
Gianmaria Baldin
SGSimona Di Giambenedetto
Simona Di Giambenedetto
Background: HIV-induced systemic immune activation and inflammation have been associated with morbidity and mortality in virologically suppressed patients. Objective: To evaluate the impact of treatment switch from a dual regimen with lamivudine (3TC) plus ritonavir-boosted protease inhibitors (PI/r) to 3TC plus dolutegravir (DTG) on the monocyte activation marker soluble CD14 (sCD14) and other inflammatory biomarkers, interleukin-6 (IL-6), C-reactive protein (CRP), intestinal fatty acid–binding protein (I-FABP) and D-dimer. Methods: We performed a retrospective case-crossover study on integrase inhibitors-naïve virologically suppressed patients while on 3TC + PI/r dual maintenance therapy for ≥48 weeks who switched to 3TC + DTG and maintained this regimen for ≥48 weeks. Biomarkers plasma levels were tested by ELISA assays on stored samples at three time points: at switch (BL), 48 weeks before (−48 W) and 48 weeks after switch (+48 W). Results: A total of 67 patients were included. Median sCD14 levels were stable from −48 W to BL (from 6.07 to 6.04 log10 pg/mL, p = 0.235) but showed a statistically significant decrease after switch: from 6.04 (IQR 5.92-6.12) at BL to 5.95 (IQR 5.84–6.07) log10 pg/mL at + W48 (p < 0.001). Concurrently, an improvement in lipid profile was observed, even thought it was not correlated to the change in sCD14. The levels of IL-6, CRP, I-FABP and D-dimer remained stable before and after the switch to 3TC + DTG. Conclusions: In virologically suppressed HIV-infected patients on a 3TC + PI/r dual therapy, switching to 3TC + DTG was associated with a significant decline in sCD14. These data suggest reduced monocyte activation following substitution of boosted PI with DTG, which could have important clinical implications.

23 September 2020 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
ABAlberto Borghetti
Alberto Borghetti
ACArturo Ciccullo
Arturo Ciccullo
FLF Lombardi
F Lombardi
GBGianmaria Baldin
Gianmaria Baldin
SBS Belmonti
S Belmonti
SGS Di Giambenedetto
S Di Giambenedetto

25 June 2019 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
ABAlberto Borghetti
Alberto Borghetti
DMD Moschese
D Moschese
ACA Cingolani
A Cingolani
GBGianmaria Baldin
Gianmaria Baldin
DSD Speziale
D Speziale
SGS Di Giambenedetto
S Di Giambenedetto